The ascension of Viagra initially drove significant expansion in the medicinal sector, generating a perception of guaranteed gains. However, placing capital in companies primarily reliant on flagship drugs like the erectile dysfunction pill presents significant challenges. Intellectual property expiry has resulted in off-brand rivalry, decreasin… Read More

The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for blockbuster treatments and impressive returns is clear, the linked risks are also notable. Many of thes… Read More